HPV vaccine: a critical component in a comprehensive cervical cancer prevention program

Vivien Tsu

UICC World Cancer Congress
Montreal, August 27-30, 2012
Background on cervical cancer

Incidence highest in low and middle income countries

- Estimated to increase from 529,828 cases in 2008 to 776,032 in 2030*

- Failure of cytology screening to have impact in low- or middle-income countries

- New prevention opportunity in form of vaccines against primary causal agent—human papillomavirus (HPV)

*Globocan, 2008
Two vaccines available

• Both highly effective against HPV types 16 and 18—responsible for ~70% of cervical cancer*

• Both very safe—no deaths, rare serious adverse events (for women with other risk factors)

• Both registered in >120 countries

• Both pre-qualified by WHO (i.e. safe and effective for UN purchase)

• Recommended by WHO for girls aged 9-13

*One also protects against non-oncogenic types, HPV 6 and 11
National and pilot introductions

43 countries – national
20 countries – pilot or demo
PATH HPV Vaccine Demonstration Projects

- Vietnam (provinces): Thanh Hoa
- Uganda (districts): Ibanda, Nakasongola
- India (states): Can Tho
- Peru (regions): Ayacucho, Arequipa
Vaccine delivery strategies

- **Schools**
  - All countries

- **Community health centers**
  - Vietnam, Peru, India (out-of-school girls)

- **Outreach programs**
  - Uganda

Over 66,000 girls eligible
Overall, coverage was high – both initial acceptance and completion

Coverage survey data, school-based delivery

<table>
<thead>
<tr>
<th></th>
<th>India (Yr1)</th>
<th>Peru (Yr1)</th>
<th>Uganda (Yr2)</th>
<th>Vietnam (Yr2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least 1 dose</td>
<td>82%</td>
<td>84%</td>
<td>96%</td>
<td>97%</td>
</tr>
<tr>
<td>All 3 doses</td>
<td>79%</td>
<td>82%</td>
<td>89%</td>
<td>96%</td>
</tr>
<tr>
<td>Completion 1 → 3</td>
<td>97%</td>
<td>98%</td>
<td>93%</td>
<td>99%</td>
</tr>
</tbody>
</table>

- Little difference in coverage between strategies: greater variance in terms of cost per vaccinated child
- Strong community mobilization efforts; careful training of health workers
Communication materials developed

- Manuals
- Leaflets
- Posters
- Fact book
- Radio spots
- Banners
Lessons learned: Factors for success

1. Secure visible government endorsement / participation.
2. Provide training for health workers, teachers, and others involved in program.
3. Engage communities through sensitization and mobilization, with strategic use of media.
4. Use pulsed schedules to facilitate community awareness and ease health worker burden.
5. Build educational messages on positive attitudes towards vaccines, prevention of cancer.
6. Have crisis communication plan in place.
7. Tailor delivery strategy. Schools can reach majority of eligible girls, with mop-up for those not in school (or absent on vaccination day).
Practical Experience Series from PATH

- Lessons learned and resources for decision-making and vaccination program planning.
  - Planning
  - Formative research
  - Vaccine implementation
  - Evaluation
  - Screening

www.rho.org/HPV-practical-experience.htm
Vaccine financing

- **Low income countries**
  - GAVI approved, 2011
  - Contingent on final price negotiated (<$5/dose) and country ability to deliver successfully

- **Middle income**
  - Price drop (~$15-30/dose)
  - PAHO Revolving Fund (~$13/dose)
GAVI opportunity

• 57 countries eligible for GAVI assistance

• 2 HPV vaccine pathways approved
  – National introduction
  – Demonstration project

• Demonstration project has 3 objectives
  1. Learn by doing, on small scale first
  2. Explore opportunities for integrating with other adolescent interventions
  3. Strengthen or develop comprehensive national cervical cancer control strategy
Many resources now available

- Online library at www.rho.org
- Action planner
WHO tools for cervical cancer prevention and control

http://www.who.int/reproductivehealth/topics/cancers/index.html
Why a comprehensive prevention approach?

• Vaccine not 100% effective – still need screening

• Issue of generational equity – many women already infected, won’t benefit from vaccine

• In long run, vaccine will ease burden on screening as there are fewer positives needing treatment

• Synergies in raising awareness about cervical cancer prevention – both screening and vaccine >> demand

• Engages broader range of stakeholders

• Allows countries to start from where they are and build accordingly
Conclusions

• Immunization is trusted, familiar, and less likely than other services to have inequities in coverage.

• Many synergies for combining screening and HPV vaccination, although timetables for introduction and scale-up may differ.

• Options for affordable screening and HPV vaccine now exist.

• In the long term, a comprehensive approach offers the biggest payoff.
Thank you

Vivien Tsu, PhD MPH
Director, HPV Vaccines Project
vtsu@path.org
www.path.org/cervicalcancer